News
-
-
-
COMMUNIQUÉ DE PRESSE
NanoViricides Awaits Approval from DR Congo Regulatory Agency for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola, Financing Completed to Support the Trial
NanoViricides, Inc. eagerly awaits approval for Phase II Clinical Trial of NV-387 Oral Gummies to treat Bundibugyo Ebolavirus in DRC. Financing secured for trial against fast-spreading Ebola outbreak -
-
-
COMMUNIQUÉ DE PRESSE
NanoViricides Announces Pricing of ~$3.8 Million Registered Direct Offering
NanoViricides, Inc. announces entering into securities purchase agreement for $3.8 million with institutional investor. Offering to be closed on July 27, 2026. Company offers broad-spectrum antivirals based on nanomedicine technology -
-
-
COMMUNIQUÉ DE PRESSE
As Ebola Death Toll Surpasses 930 Within Two Months, NanoViricides Has Applied to the DR Congo Regulatory Agency for Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola
NanoViricides, Inc. applies for Phase II Clinical Trial of NV-387 Oral Gummies as Treatment for Bundibugyo Ebolavirus in DRC, aiming to combat Ebola outbreak with revolutionary antiviral drug -
